Published by Global Banking & Finance Review®
Posted on May 7, 2025
1 min readLast updated: January 24, 2026
The EMA is reviewing Valneva's chikungunya vaccine after reports of serious side effects in seniors, leading to temporary use restrictions for those 65 and older.
(Reuters) - The European Union's health regulator said on Wednesday it was reviewing Valneva's chikungunya vaccine after reports of serious side effects in older adults.
The European Medicines Agency's (EMA) safety committee has recommended temporarily restricting the use of the vaccine, branded as Ixchiq, in adults aged 65 years and older.
About 17 serious adverse events, including two deaths, have been reported so far globally in people aged between 62 and 89 years who had received the vaccine, the EMA said in a statement.
The exact cause of the side effects and their relationship with the vaccine have not yet been determined, the agency said, adding that the affected individuals also had other health conditions.
(Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Shinjini Ganguli)
The main topic is the EMA's review of Valneva's chikungunya vaccine due to reports of serious side effects in older adults.
The EMA recommends temporarily restricting the vaccine's use in adults aged 65 and older.
Seventeen serious adverse events, including two deaths, have been reported globally.
Explore more articles in the Headlines category
